Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAF
Cell Discov. 2022;8(1):102
We thank Andrea Viale and Alessandro Carugo at the University of Texas MD Anderson Cancer Center (MDACC) for helpful discussion; Ying Hu at the National Institutes of Health/National Cancer Institute (NIH/NCI) for help in adjusting the Circos plot parameters. We thank Jerome Karp at NYU Langone Health for proofreading. Next-generation sequencing was performed by the NYU Langone Genome Technology Center, which is supported in part by grant P30CA016087 from NIH/NCI. Cell sorting/flow cytometry technologies were provided by NYU Langone’s Cytometry and Cell Sorting Laboratory (supported in part by grant P30CA016087) and the MDACC Flow Cytometry and Cellular Imaging Core Facility (supported by NCI grant P30CA16672). STR DNA fingerprinting was done by the Cancer Center Support Grant-funded Characterized Cell Line core (supported by NCI grant CA016672). This study was supported by R01 CA190121-01 (Z.-Y.Z., R.G.W.V., and E.P.S.) and by the DefeatGBM collaborative of the National Brain Tumor Association (Q.W. and E.P.S.).
Targeted cancer therapies have revolutionized treatment but their efficacies are limited by the development of resistance driven by clonal evolution within tumors. We developed "CAPTURE", a single-cell barcoding approach to comprehensively trace clonal dynamics and capture live lineage-coupled resistant cells for in-depth multi-omics analysis and functional exploration. We demonstrate that heterogeneous clones, either preexisting or emerging from drug-tolerant persister cells, dominated resistance to vemurafenib in BRAF
Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAF Cell Discov. 2022;8(1):102
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.